Evidence map›Paper›PMID 28190076›Full record

ArticleJournal of visualized experiments : JoVE2017

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle.

Hironori Nishitsuji, Hiromi Yamamoto, Ritsuko Shiina, Keisuke Harada, Saneyuki Ujino, Kunitada Shimotohno

Abstract readVideo-Audio Media
In one paragraph

Article in Journal of visualized experiments : JoVE, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Hironori NishitsujiResearch Center for Hepatitis and Immunology, National Center for Global Health and Medicine; lbnishitsuji@hospk.ncgm.go.jp.
Hiromi YamamotoResearch Center for Hepatitis and Immunology, National Center for Global Health and Medicine.
Ritsuko ShiinaResearch Center for Hepatitis and Immunology, National Center for Global Health and Medicine.
Keisuke HaradaCentral Pharmaceutical Research Institute, Japan Tobacco Inc.
Saneyuki UjinoResearch Center for Hepatitis and Immunology, National Center for Global Health and Medicine.
Kunitada ShimotohnoResearch Center for Hepatitis and Immunology, National Center for Global Health and Medicine.
Center for Global Health · USJapan Tobacco (Japan) · JPNational Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, it is possible to construct recombinant forms of various viruses, such as human immunodeficiency virus 1 (HIV-1) and hepatitis C virus (HCV), that carry foreign genes such as a reporter or marker protein in their genomes. These recombinant viruses usually faithfully mimic the life cycle of the original virus in infected cells and exhibit the same host range dependence. The development of a recombinant virus enables the efficient screening of inhibitors and the identification of specific host factors. However, to date the construction of recombinant hepatitis B virus (HBV) has been difficult because of various experimental limitations. The main limitation is the compact genome size of HBV, and a fairly strict genome size that does not exceed 1.3 genome sizes, that must be packaged into virions. Thus, the size of a foreign gene to be inserted should be smaller than 0.4 kb if no deletion of the genome DNA is to be performed. Therefore, to overcome this size limitation, the deletion of some HBV DNA is required. Here, we report the construction of recombinant HBV encoding a reporter gene to monitor the early stage of the HBV replication cycle by replacing part of the HBV core-coding region with the reporter gene by deleting part of the HBV pol coding region. Detection of recombinant HBV infection, monitored by the reporter activity, was highly sensitive and less expensive than detection using the currently available conventional methods to evaluate HBV infection. This system will be useful for a number of applications including high-throughput screening for the identification of anti-HBV inhibitors, host factors and virus-susceptible cells.

Indexed as

DNA, ViralGenes, ReporterGenome, ViralHepatitis B virusHep G2 CellsHumansTransfectionVirionVirus ReplicationDNA, Viral

Identifiers

PMID28190076
PMCPMC5407679
OpenAlexW2585639625

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.